Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Metastatic Neuroendocrine Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Burkitt Lymphoma 1

Interventions

Imatinib Mesylate 3fludarabine phosphate 2fludarabine 2Acetaminophen 2thymoglobulin 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Melphalan 1Magnetic Resonance Imaging 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Cyclophosphamide 1Clofarabine 1Busulfan 1Bone Marrow Transplantation 1Blood Specimen Collection 1Blood Component Removal 1Azacitidine 1Antilymphocyte Serum 1Antiemetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Philadelphia Chromosome × Antiemetics × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡